Keyphrases
Secukinumab
100%
Axial Spondyloarthritis (AxSpA)
96%
Psoriatic Arthritis
50%
Patient-reported Outcomes
30%
Targeted Synthetic Disease-modifying Antirheumatic Drugs
30%
Arthritis Patients
30%
Routine Care
30%
Remission
28%
Low Disease Activity
27%
Daily Clinical Practice
25%
Non-radiographic Axial Spondyloarthritis
25%
Treatment Outcome
25%
Real Patients
25%
Treatment Response
25%
Continuation Treatment
25%
Scientific Networks
25%
Retention Rate
22%
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
19%
Remission Rate
17%
C-reactive Protein
14%
Disease Activity Score
13%
Drug Retention
12%
Nave
11%
Activity Rate
11%
Ankylosing Spondylitis Disease Activity Score (ASDAS)
9%
Health Assessment Questionnaire
8%
Logistic Regression Analysis
8%
European Registries
8%
Inactive Disease
6%
Adjusted Analysis
5%
Numeric Rating Scale
5%
HLA-B27
5%
Patient Global Assessment
5%
Cox Regression Analysis
5%
Kaplan-Meier Plot
5%
Pharmacology, Toxicology and Pharmaceutical Science
Secukinumab
100%
Spondylarthritis
100%
Psoriatic Arthritis
50%
Disease Activity
43%
Remission
38%
Disease Modifying Antirheumatic Drug
28%
Observational Study
25%
Ankylosing Spondylitis
18%
Disease Activity Score
12%
C Reactive Protein
10%
Medicine and Dentistry
Observational Study
25%
Secukinumab
25%
Spondylarthritis
25%
Drug Retention
6%
